{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:44:28Z","timestamp":1780789468357,"version":"3.54.1"},"reference-count":48,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.1188\/10.cjon.223-233","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T21:21:41Z","timestamp":1270675301000},"page":"223-233","source":"Crossref","is-referenced-by-count":24,"title":["Lapatinib Side-Effect Management"],"prefix":"10.1188","volume":"14","author":[{"given":"Cynthia","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances M.","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2010,3,29]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"A. Agero","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1634\/theoncologist.5-3-250","article-title":"The consequences of diarrhea occurring during chemotherapy for colorectal cancer: A retrospective study","volume":"5","author":"R. Arbuckle","year":"2000","journal-title":"Oncologist"},{"key":"3","first-page":"227","article-title":"Clinical implications of chemotherapy-induced diarrhea in patients with cancer","volume":"3","author":"R. Arnold","year":"2005","journal-title":"Journal of Supportive Oncology"},{"key":"4","unstructured":"AstraZeneca Pharmaceuticals LP. (2005). <i>Iressaa<\/i> [Package insert]. Wilmington, DE: Author."},{"key":"5","first-page":"663","article-title":"Intestinal lesions induced experimentally by methotrexate","volume":"58","author":"A. Baskerville","year":"1977","journal-title":"British Journal of Experimental Pathology"},{"key":"6","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"A. Benson, III","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"7","unstructured":"Bristol-Myers Squibb Co. (2003). <i>Taxola<\/i> [Package insert]. Princeton, NJ: Author."},{"key":"8","first-page":"205","article-title":"Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCI in patients with metastatic breast cancer (MBC) [Abstract]","volume":"22","author":"R. Bruno","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"9","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"H. Burris, III","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10","article-title":"A phase I, open-label study of the safety, tolerability, and pharmacokinetics of lapatinib in combination with paclitaxel in patients with solid tumors","author":"H. Burris, III","journal-title":"Clinical Cancer Research"},{"key":"11","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study","volume":"23","author":"B. Burtness","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"K. Busam","year":"2001","journal-title":"British Journal of Dermatology"},{"key":"13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses","volume":"112","author":"D. Cameron","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"14","first-page":"196","article-title":"Rash severity is predictive of increased survival with erlotinib HCI [Abstract]","volume":"22","author":"G. Clarke","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"15","article-title":"A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [Abstract 1]","volume":"100","author":"M. Cristofanilli","year":"2006","journal-title":"Breast Cancer Research and Treatment"},{"key":"16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","article-title":"Pooled analysis of diarrhea events in patients with cancer treated with lapatinib","volume":"112","author":"J. Crown","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory meta-static colorectal cancer","volume":"351","author":"D. Cunningham","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"18","article-title":"Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed\/amplified breast cancer (BC): First safety results [Abstract 1810]","volume":"19","author":"C. Dang","year":"2008","journal-title":"Annals of Oncology"},{"key":"19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0014-4800(92)90027-9","article-title":"Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats","volume":"56","author":"D. de Roy van Zuidewijn","year":"1992","journal-title":"Experimental and Molecular Pathology"},{"key":"20","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"A. Di Leo","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1200\/jco.2005.23.16_suppl.3583","article-title":"An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [Abstract]","volume":"23","author":"A. Fields","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"22","unstructured":"Genentech, Inc. (2008). <i>Herceptina<\/i> [Package insert]. San Francisco, CA: Author."},{"key":"23","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"C. Geyer","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"24","unstructured":"GlaxoSmithKline. (2008). <i>Tykerba<\/i> [Package insert]. Research Triangle Park, NC: Author."},{"key":"25","unstructured":"ImClone Systems Inc. (2007). <i>Erbituxa<\/i> [Package insert]. Branchburg, NJ: Author."},{"key":"26","article-title":"Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: Initial safety data from the Mayo Clinic Cancer Research Consortium Trial RC0639","author":"B. Johnson","year":"2008"},{"key":"27","first-page":"1","article-title":"Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage","volume":"63","author":"C. Kari","year":"2003","journal-title":"Cancer Research"},{"key":"28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0885-3924(99)00149-9","article-title":"Management of cancer treatment-related diarrhea: Issues and therapeutic strategies","volume":"19","author":"S. Kornblau","year":"2000","journal-title":"Journal of Pain and Symptom Management"},{"issue":"11","key":"29","first-page":"17","article-title":"Clinical management of EGFRI dermatologic toxicities: US perspective","volume":"21","author":"M. Lacouture","year":"2007","journal-title":"Oncology"},{"key":"30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"M. Lacouture","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (papulopustules and\/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"M. Lacouture","year":"2006","journal-title":"British Journal of Dermatology"},{"key":"32","unstructured":"National Cancer Institute. (1999). Cancer Therapy Evaluation Program. Common Terminology Criteria [version 2.0]. Retrieved from <a target=\"_blank\" href='http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf'>http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf<\/a>"},{"key":"33","unstructured":"National Cancer Institute. (2006). Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events [version 3.0]. Retrieved from <a target=\"_blank\" href='http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf'>http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf<\/a>"},{"key":"34","unstructured":"OSI Pharmaceuticals, Inc. (2007). <i>Tarcevaa<\/i> [Package insert]. Melville, NY: Author."},{"issue":"1","key":"35","article-title":"Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer","volume":"8","author":"R. Perez-Soler","year":"2006","journal-title":"Clinical Lung Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"R. Perez-Soler","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"37","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining?","volume":"23","author":"R. Perez-Soler","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"38","first-page":"29","article-title":"Clinical management of EGFRI dermatologic toxicities: The nursing perspective","volume":"21","author":"M. Purdom","year":"2007","journal-title":"Oncology"},{"issue":"18","key":"39","article-title":"Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC) [Abstract 4502]","volume":"24","author":"A. Ravaud","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"40","unstructured":"Roche Pharmaceuticals. (2006). <i>Xelodaa<\/i> [Package insert]. Nutley, NJ: Author."},{"issue":"16","key":"41","article-title":"Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer [Abstract 7099]","volume":"23","author":"H. Ross","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"42","unstructured":"sanofi-aventis. (2006). <i>Taxoterea<\/i> [Package insert]. Bridgewater, NJ: Author."},{"key":"43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"S. Segaert","year":"2005","journal-title":"Annals of Oncology"},{"key":"44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1470-2045(05)01735-3","article-title":"Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea","volume":"6","author":"R. Sharma","year":"2005","journal-title":"Lancet Oncology"},{"issue":"1","key":"45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.soncn.2006.01.013","article-title":"Common side effects of anti-EGFR therapy: Acneform rash","volume":"22","author":"R. Sipples","year":"2006","journal-title":"Seminars in Oncology Nursing"},{"key":"46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1995.13.1.222","article-title":"Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea","volume":"13","author":"S. Wadler","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"47","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"L. Wagner","year":"2007","journal-title":"Oncology"},{"issue":"16","key":"48","article-title":"A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced\/metastatic transitional cell carcinoma (TCC) of the urothelial tract [Abstract 4594]","volume":"23","author":"C. W\u00fclfing","year":"2005","journal-title":"Journal of Clinical Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/E166L70518M58345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:28Z","timestamp":1763754568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/14\/2\/lapatinib-side-effect-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,29]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4,1]]}},"alternative-id":["E166L70518M58345"],"URL":"https:\/\/doi.org\/10.1188\/10.cjon.223-233","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,29]]}}}